hERG channel trafficking: novel targets in drug-induced long QT syndrome
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The cardiac potassium channel hERG (human ether-a-go-go-related gene) encodes the α-subunit of the rapid delayed rectifier current IKr in the heart, which contributes to terminal repolarization in human cardiomyocytes. Direct block of hERG/IKr channels by a large number of therapeutic compounds produces acLQTS [acquired LQTS (long QT syndrome)] characterized by drug-induced QT prolongation and torsades de pointes arrhythmias. The cardiotoxicity associated with unintended hERG block has prompted pharmaceutical companies to screen developmental compounds for hERG blockade and made hERG a major target in drug safety programmes. More recently, a novel form of acLQTS has been discovered that may go undetected in most conventional safety assays. Several therapeutic compounds have been identified that reduce hERG/IKr currents not by direct block but by inhibition of hERG/IKr trafficking to the cell surface. Important examples are antineoplastic Hsp90 (heat-shock protein 90) inhibitors such as (i) geldanamycin, (ii) the leukaemia drug arsenic trioxide, (iii) the antiprotozoical pentamidine, (iv) probucol, a cholesterol-lowering drug, and (v) fluoxetine, a widely used antidepressant. Increased awareness of drug-induced hERG trafficking defects will help to further reduce the potentially lethal adverse cardiac events associated with acLQTS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ich function is dependent upon their appropriate location and abundance within the cells, which is regulated by a delicate equilibrium between endocytic, secretory, and degradative pathways [79,80,81].”
From Insights of Endocytosis Signaling in Health and Disease (2023) · cites this paper as [81]
Citations
Cites
Sanguinetti, M. C., Jiang, C., Curran, M. E., & Keating, M. T. (1995) · Cell · doi:10.1016/0092-8674(95)90340-2 · Cited by 2,423
hERG potassium channels and cardiac arrhythmia
Sanguinetti, M. C., & Tristani-Firouzi, M. (2006) · Nature · doi:10.1038/nature04710 · Cited by 1,572
Molecular and Cellular Mechanisms of Cardiac Arrhythmias
Keating, M. T., & Sanguinetti, M. C. (2001) · Cell · doi:10.1016/s0092-8674(01)00243-4 · Cited by 1,001
Hieronymus, H., Lamb, J., Ross, K. N., Peng, X. P., Clement, C., Rodina, A., Nieto, M., Du, J., Stegmaier, K., Raj, S. M., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.005 · Cited by 624
Heat shock protein 90 as a molecular target for cancer therapeutics
Isaacs, J. S., Xu, W., & Neckers, L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00029-1 · Cited by 577
The impact of drug-induced QT interval prolongation on drug discovery and development
Fermini, B., & Fossa, A. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1108 · Cited by 492
Most LQT2 Mutations Reduce Kv11.1 (hERG) Current by a Class 2 (Trafficking-Deficient) Mechanism
Anderson, C. L., Delisle, B. P., Anson, B. D., Kilby, J. A., Will, M. L., Tester, D. J., Gong, Q., Zhou, Z., Ackerman, M. J., & January, C. T. (2006) · Circulation · doi:10.1161/circulationaha.105.570200 · Cited by 408
Drug‐Induced Torsades de Pointes and Implications for Drug Development
FENICHEL, R. R., MALIK, M., ANTZELEVITCH, C., SANGUINETTI, M., RODEN, D. M., PRIORI, S. G., RUSKIN, J. N., LIPICKY, R. J., CANTILENA, L. R., & Independent Academic Task Force (2004) · Journal of Cardiovascular Electrophysiology · doi:10.1046/j.1540-8167.2004.03534.x · Cited by 346
Role of the Cytosolic Chaperones Hsp70 and Hsp90 in Maturation of the Cardiac Potassium Channel hERG
Ficker, E., Dennis, A. T., Wang, L., & Brown, A. M. (2003) · Circulation Research · doi:10.1161/01.res.0000079028.31393.15 · Cited by 323
Self-citationPredicting drug–hERG channel interactions that cause acquired long QT syndrome
Sanguinetti, M. C., & Mitcheson, J. S. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.01.003 · Cited by 300
Cited by
Voltage-gated potassium channels as therapeutic targets
Wulff, H., Castle, N. A., & Pardo, L. A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2983 · Cited by 799
The hERG potassium channel and hERG screening for drug-induced torsades de pointes
Hancox, J. C., McPate, M. J., El Harchi, A., & Zhang, Y. H. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.05.009 · Cited by 299
Gintant, G. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.08.008 · Cited by 222
Andrade, E. L., Bento, A. F., Cavalli, J., Oliveira, S. K., Schwanke, R. C., Siqueira, J. M., Freitas, C. S., Marcon, R., & Calixto, J. B. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20165646 · Cited by 184
Lu, Z., Wu, C.-Y. C., Jiang, Y.-P., Ballou, L. M., Clausen, C., Cohen, I. S., & Lin, R. Z. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003623 · Cited by 172
Florian, J. A., Tornøe, C. W., Brundage, R., Parekh, A., & Garnett, C. E. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010381498 · Cited by 170
Refining the Human iPSC-Cardiomyocyte Arrhythmic Risk Assessment Model
Guo, L., Coyle, L., Abrams, R. M. C., Kemper, R., Chiao, E. T., & Kolaja, K. L. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft205 · Cited by 145
The role of heat shock proteins and co-chaperones in heart failure
Ranek, M. J., Stachowski, M. J., Kirk, J. A., & Willis, M. S. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0530 · Cited by 139
Human ether-a-go-go related gene (hERG) K+ channels: Function and dysfunction
Perrin, M. J., Subbiah, R. N., Vandenberg, J. I., & Hill, A. P. (2008) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2008.10.006 · Cited by 126
Abassi, Y. A., Xi, B., Li, N., Ouyang, W., Seiler, A., Watzele, M., Kettenhofen, R., Bohlen, H., Ehlich, A., Kolossov, E., et al. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01623.x · Cited by 124
Shah, R. R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00191.x · Cited by 114
Cavero, I., & Holzgrefe, H. H. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.915311 · Cited by 101
Control of Cardiac Repolarization by Phosphoinositide 3-Kinase Signaling to Ion Channels
Ballou, L. M., Lin, R. Z., & Cohen, I. S. (2014) · Circulation Research · doi:10.1161/circresaha.116.303975 · Cited by 92
Key Characteristics of Cardiovascular Toxicants
Lind, L., Araujo, J. A., Barchowsky, A., Belcher, S. M., Berridge, B. R., Chiamvimonvat, N., Chiu, W. A., Cogliano, V. J., Elmore, S., Farraj, A. K., et al. (2021) · Environmental Health Perspectives · doi:10.1289/ehp9321 · Cited by 91
Shan, H., Zhang, Y., Cai, B., Chen, X., Fan, Y., Yang, L., Chen, X., Liang, H., Zhang, Y., Song, X., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.07.009 · Cited by 88
Gintant, G. A. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.04.010 · Cited by 87
Delayed rectifier K+ currents and cardiac repolarization
Charpentier, F., Mérot, J., Loussouarn, G., & Baró, I. (2009) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2009.08.005 · Cited by 85
Huang, X.-P., Mangano, T., Hufeisen, S., Setola, V., & Roth, B. L. (2010) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2010.0331 · Cited by 83
Zhang, X., Guo, L., Zeng, H., White, S., Furniss, M. J., Balasubramanian, B., Lis, E. V., Lagrutta, A., Sannajust, F. J., Zhao, L. L., et al. (2016) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2016.06.004 · Cited by 77
Cardiac Delayed Rectifier Potassium Channels in Health and Disease
Chen, L., Sampson, K. J., & Kass, R. S. (2016) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2016.01.004 · Cited by 73
Drug‐Induced QT‐Interval Prolongation: Considerations for Clinicians
Li, E. C., Esterly, J. S., Pohl, S., Scott, S. D., & McBride, B. F. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.7.684 · Cited by 72
Chu, W., Li, C., Qu, X., Zhao, D., Wang, X., Yu, X., Cai, F., Liang, H., Zhang, Y., Zhao, X. Y., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs230 · Cited by 72
Molecular Determinants of Pentamidine-Induced hERG Trafficking Inhibition
Dennis, A. T., Wang, L., Wan, H., Nassal, D. M., Deschênes, I., & Ficker, E. K. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.075135 · Cited by 71
Self-citationVaradarajan, S., Bampton, E. T. W., Smalley, J. L., Tanaka, K., Caves, R. E., Butterworth, M., Wei, J., Pellecchia, M., Mitcheson, J. S., Gant, T. W., et al. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.108 · Cited by 69
Experimentally Validated hERG Pharmacophore Models as Cardiotoxicity Prediction Tools
Kratz, J. M., Schuster, D., Edtbauer, M., Saxena, P., Mair, C. E., Kirchebner, J., Matuszczak, B., Baburin, I., Hering, S., & Rollinger, J. M. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci5001955 · Cited by 65
Wu, Q., Bai, B., Tian, C., Li, D., Yu, H., Song, B., Li, B., & Chu, X. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07181-3 · Cited by 64
Darpö, B., Garnett, C. E., Benson, C., Keirns, J. J., Leishman, D. J., Malík, M., Mehrotra, N., Prasad, K., Riley, S., Rodríguez, I., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.06.003 · Cited by 63
Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance
Cubeddu, L. X. (2009) · Current Cardiology Reviews · doi:10.2174/157340309788970397 · Cited by 63
Insights of Endocytosis Signaling in Health and Disease
Pathak, C., Vaidya, F. U., Waghela, B. N., Jaiswara, P. K., Gupta, V. K., Kumar, A., Rajendran, B. K., & Ranjan, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032971 · Cited by 59
Pharmacology of Cardiac Potassium Channels
Li, G., & Dong, M. (2010) · Advances in pharmacology · doi:10.1016/s1054-3589(10)59004-5 · Cited by 58
Implications of the IQ-CSRC Prospective Study: Time to Revise ICH E14
Darpö, B., Garnett, C. E., Keirns, J. J., & Stockbridge, N. (2015) · Drug Safety · doi:10.1007/s40264-015-0325-5 · Cited by 56
Antidepressant-induced Ubiquitination and Degradation of the Cardiac Potassium Channel hERG
Dennis, A. T., Nassal, D. M., Deschênes, I., Thomas, D., & Ficker, E. K. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.254367 · Cited by 51
Self-citationZheng, Z., Wu, Y., Qian, D., & Jiangfang, L. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173813 · Cited by 49
Zhang, Y., Dong, Z., Jin, L., Zhang, K., Zhao, X. Y., Fu, J., Gong, Y., Sun, M., Yang, B., & Li, B. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.09.002 · Cited by 48
Reddy, N. M., Voorhees, P. M., Houk, B. E., Brega, N. M., Hinson, J. M., & Jillela, A. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.03.010 · Cited by 46
Endocytosis: A Turnover Mechanism Controlling Ion Channel Function
Estadella, I., Pedrós-Gámez, O., Colomer-Molera, M., Bosch, M., Sorkin, A. D., & Felipe, A. (2020) · Cells · doi:10.3390/cells9081833 · Cited by 45
Apaja, P. M., Foo, B., Okiyoneda, T., Valinsky, W. C., Barriere, H., Atanasiu, R., Ficker, E., Lukacs, G. L., & Shrier, A. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e13-07-0417 · Cited by 45
Self-citationMorganroth, J., Shah, R. R., & Scott, J. W. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.214 · Cited by 41
Stummann, T. C., Beilmann, M., Duker, G., Dumotier, B. M., Fredriksson, J. M., Jones, R. L., Hasiwa, M., Kang, Y. J., Mandenius, C., Meyer, T. S., et al. (2009) · Cardiovascular Toxicology · doi:10.1007/s12012-009-9045-3 · Cited by 41
Obers, S., Staudacher, I., Ficker, E. K., Dennis, A. T., Koschny, R., Erdal, H., Bloehs, R., Kisselbach, J., Karle, C. A., Schweizer, P. A., et al. (2010) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-010-0496-7 · Cited by 41
Self-citationImpaired surface expression and conductance of the KCNQ 4 channel lead to sensorineural hearing loss
Gao, Y., Yechikov, S., Vázquez, A. E., Chen, D., & Nie, L. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12080 · Cited by 39
Distinct Roles of Molecular Chaperones HSP90α and HSP90β in the Biogenesis of KCNQ4 Channels
Gao, Y., Yechikov, S., Vázquez, A. E., Chen, D., & Nie, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057282 · Cited by 38
Histone Deacetylase Inhibitors Prolong Cardiac Repolarization through Transcriptional Mechanisms
Spence, S., Deurinck, M., Ju, H., Traebert, M., McLean, L., Marlowe, J. L., Emotte, C., Tritto, E., Tseng, M., Shultz, M. D., et al. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw104 · Cited by 37
Impact of ABCB1 Allelic Variants on QTc Interval Prolongation
Sissung, T. M., Gardner, E. R., Piekarz, R., Howden, R., Chen, X., Woo, S., Franke, R. M., Clark, J. A., Miller‐DeGraff, L., Steinberg, S. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0925 · Cited by 37
Baburin, I., Varkevisser, R., Schramm, A., Saxena, P., Beyl, S., Szkokan, P., Linder, T., Stary‐Weinzinger, A., van der Heyden, M. A. G., Houtman, M. J. C., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.024 · Cited by 37
Kraushaar, U., Meyer, T., Hess, D., Gepstein, L., L Mummery, C., R Braam, S., & Guenther, E. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.639358 · Cited by 36
Mechanisms of acquired long QT syndrome in patients with propionic academia
Bódi, I., Grünert, S. C., Becker, N., Stoelzle‐Feix, S., Spiekerkoetter, U., Zehender, M., Bugger, H., Bode, C., & Odening, K. E. (2016) · Heart Rhythm · doi:10.1016/j.hrthm.2016.02.003 · Cited by 35
Assessment of temperature‐induced hERG channel blockade variation by drugs
Kauthale, R. R., Dadarkar, S. S., Husain, R., Karande, V. V., & Gatne, M. M. (2014) · Journal of Applied Toxicology · doi:10.1002/jat.3074 · Cited by 34
High Glucose Represses hERG K+ Channel Expression through Trafficking Inhibition
Shi, Y., Yan, M., Liu, L., Zhang, X., Wang, X., Geng, H., Zhao, X., & Li, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000430353 · Cited by 30
Liu, T., Li, T., Xu, D., Wang, Y., Zhou, Y., Wan, J., Huang, C. L.-H., & Tan, X. (2023) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2022.0171 · Cited by 28
Dumotier, B. M., Deurinck, M., Yang, Y.-S., Traebert, M., & Suter, W. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.03.001 · Cited by 28
Hamburger, M. O. (2019) · Pharmaceutical Biology · doi:10.1080/13880209.2019.1606261 · Cited by 27
Cardiac ion channel trafficking defects and drugs
de Git, K. C. G., de Boer, T. P., Vos, M. A., & van der Heyden, M. A. G. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.03.008 · Cited by 27
Ion channel trafficking: A new therapeutic horizon for atrial fibrillation
Schumacher, S. M., & Martens, J. R. (2010) · Heart Rhythm · doi:10.1016/j.hrthm.2010.02.017 · Cited by 26
Characterization of Influenza Virus Pseudotyped with Ebolavirus Glycoprotein
Xiao, J. H., Rijal, P., Schimanski, L. M., Tharkeshwar, A. K., Wright, E., Annaert, W. G., & Townsend, A. (2017) · Journal of Virology · doi:10.1128/jvi.00941-17 · Cited by 25
hERG in vitro interchange factors—development and verification
Wiśniowska, B., & Polak, S. (2009) · Toxicology Mechanisms and Methods · doi:10.1080/15376510902777194 · Cited by 24
Tanaka, H., Takahashi, Y., Hamaguchi, S., Iida‐Tanaka, N., Oka, T., Nishio, M., Ohtsuki, A., & Namekata, I. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00417 · Cited by 22
Practice and challenges of thorough QT studies
Stockbridge, N., Zhang, J., Garnett, C. E., & Malík, M. (2012) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2012.07.020 · Cited by 22
Feng, P., Zhang, B., Zhao, L., Fang, Q. Z., Liu, Y., Wang, J., Xu, X., Xue, H. Y., Li, Y., Yan, M., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01102 · Cited by 22
Mechanisms underlying probucol-induced hERG-channel deficiency
Li, B., Shi, Y., Li, B., Zhang, X., Liu, L., Geng, H., Lv, L. L., & Yan, M. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s86724 · Cited by 20
The rescuable function and mechanism of resveratrol on As2O3-induced hERG K+ channel deficiency
Zhao, X. Y., Zhang, K.-P., Huang, T., Yan, C., Liu, L., Zhu, Q.-L., Guo, F.-F., Liu, C., & Li, B. (2014) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-014-1019-8 · Cited by 20
Iachetta, G., Melle, G., Colistra, N., Tantussi, F., Angelis, F. D., & Dipalo, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-022-03422-y · Cited by 20
In vitro chronic effects on hERG channel caused by the marine biotoxin azaspiracid-2
Ferreiro, S. F., Vilariño, N., Louzao, M. C., Nicolaou, K. C., Frederick, M. O., & Botana, L. M. (2014) · Toxicon · doi:10.1016/j.toxicon.2014.09.012 · Cited by 20
Apáti, Á., Varga, N., Berecz, T., Erdei, Z., Homolya, L., & Sarkadi, B. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1558207 · Cited by 19
Lee, B. H., Lee, S. H., Chu, D., Hyun, J. W., Choe, H., Choi, B. H., & Jo, S. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.66 · Cited by 19
Heat stroke, an unusual trigger of Brugada electrocardiogram
Lacunza, J., Román, I. S., Moreno, S., García-Molina, E., Gimeno, J. R., & Valdés, M. (2009) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2008.09.036 · Cited by 18
Cardiac slices as a predictive tool for arrhythmogenic potential of drugs and chemicals
Meyer, T. S., Stuerz, K., Guenther, E., Edamura, M., & Kraushaar, U. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.526601 · Cited by 17
Asahi, Y., Nomura, F., Abe, Y., Doi, M., Sakakura, T., Takasuna, K., & Yasuda, K. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.10.046 · Cited by 17
Ulivieri, A., Lavra, L., Magi, F., Morgante, A., Calò, L., Polisca, P., Salehi, L. B., & Sciacchitano, S. (2022) · Scientific Reports · doi:10.1038/s41598-021-04659-w · Cited by 16
Shah, R. R. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.03.002 · Cited by 16
Genetics of Sudden Cardiac Arrest
Prutkin, J. M., & Sotoodehnia, N. (2008) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2007.10.006 · Cited by 15
Kumazaki, M., Ando, H., Kakei, M., Ushijima, K., Taniguchi, Y., Yoshida, M., Yamato, S., Washino, S., Koshimizu, T., & Fujimura, A. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.02.027 · Cited by 15
Cardiac Involvement in Patients with Hematologic Malignancies
Allegra, A., Alonci, A., Russo, S., Cannavò, A., Penna, G., D’Angelo, A., Bellomo, G., & Musolino, C. (2010) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3181efbc4e · Cited by 15
Wang, Q., Hu, W., Lei, M., Wang, Y., Yan, B., Liu, J., Zhang, R., & Jin, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084984 · Cited by 14
Maciel, N. R., dos Reis, P. G., Kato, K. C., Vidal, A. T., Guimarães, H. N., Frézard, F., Silva-Barcellos, N. M., & Grabe‐Guimarães, A. (2010) · Toxicology Letters · doi:10.1016/j.toxlet.2010.09.004 · Cited by 14
Townsend, C. Y., & Brown, B. S. (2013) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1016s61 · Cited by 13
In Vitro and In Silico Risk Assessment in Acquired Long QT Syndrome: The Devil Is in the Details
Lee, W., Windley, M. J., Vandenberg, J. I., & Hill, A. P. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00934 · Cited by 13
Effects of cariprazine on hERG 1A and hERG 1A/3.1 potassium channels
Lee, H. J., Choi, B. H., Choi, J., & Hahn, S. J. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.04.006 · Cited by 13
Inhibition of hERG Channel Trafficking: An Under‐Explored Mechanism for Drug‐Induced QT Prolongation
Yeung, K., & Meanwell, N. A. (2008) · ChemMedChem · doi:10.1002/cmdc.200800170 · Cited by 13
Hsp90 pan and Isoform-Selective Inhibitors as Sensitizers for Cancer Immunotherapy
Jia, S., Maurya, N., Blagg, B. S. J., & Lü, X. (2025) · Pharmaceuticals · doi:10.3390/ph18071025 · Cited by 12
Cai, Y., Wang, Y., Xu, J., Zuo, X., & Xu, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.09.014 · Cited by 11
Fischer, F., Vonderlin, N., Seyler, C., Zitron, E., Schernus, B., Katus, H. A., & Scholz, E. P. (2013) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-013-0878-8 · Cited by 10
Evaluating the QT-Liability of a Drug during its Development
Shah, R. R., & Morganroth, J. (2008) · Pharmaceutical Medicine · doi:10.1007/bf03256697 · Cited by 10
Braña, I., Zamora, E., Oristrell, G., & Tabernero, J. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-70253-7_14 · Cited by 10
β-Arrestin-Mediated Regulation of the Human Ether-a-go-go-Related Gene Potassium Channel
Sangoi, M., Lamothe, S. M., Guo, J. X., Yang, T., Li, W., Avery, E. G., Fisher, J. T., & Zhang, S. (2017) · Molecular Pharmacology · doi:10.1124/mol.116.108035 · Cited by 9
Using iPSC Models to Probe Regulation of Cardiac Ion Channel Function
Bruyneel, A. A. N., McKeithan, W. L., Feyen, D. A. M., & Mercola, M. A. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1000-0 · Cited by 8
Schalkwijk, S. J., Sahota, T., Verheijen, R. B., Harmer, A. R., & Ahmed, G. F. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00573-1 · Cited by 8
Pero, J. E., Mueller, E. A., Adams, A. M., Adolph, R. S., Bagchi, P., Balce, D. R., Bantscheff, M., Barauskas, O., Bartha, I., Bohan, D., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01402 · Cited by 8
Self-citationProbucol-induced hERG Channel Reduction can be Rescued by Matrine and Oxymatrinein vitro
Shi, Y., Fan, P., Zhang, G.-C., Zhang, Y.-H., Li, M., Wang, F., & Li, B. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191026170033 · Cited by 8
Li, G., Cheng, G., Wu, J., Ma, S., Zhang, A., Han, W., & Sun, C. (2014) · Cardiology · doi:10.1159/000357232 · Cited by 8
Sama‐ae, I., Muengthongon, P., Tohlaeh, A., Rukhachan, W., Kiattikul, P., Samaeng, F., Mitklin, A., Rahman, M. A., Tedasen, A., Kwankaew, P., et al. (2025) · Scientifica · doi:10.1155/sci5/8838031 · Cited by 7
Peptidomimetic Star Polymers for Targeting Biological Ion Channels
Chen, R., Lu, D., Xie, Z., Feng, J. Q., Jia, Z., Ho, J., Coote, M. L., Wu, Y., Monteiro, M. J., & Chung, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152169 · Cited by 6
Townsend, C. Y. (2014) · Circulation · doi:10.1161/circulationaha.114.010819 · Cited by 5
Hihara, T., Yamazaki, K., Taniguchi, T., Yoshinaga, T., Ito, M., & Sawada, K. (2014) · Pharmacology & Pharmacy · doi:10.4236/pp.2014.54044 · Cited by 5
Metals and Cardiovascular Disease
Barchowsky, A., & Ufelle, A. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95642-3 · Cited by 4
Darpö, B., Bullingham, R. E. S., Combs, D. L., Ferber, G., & Hafez, K. (2013) · Cardiology Journal · doi:10.5603/cj.2013.0028 · Cited by 4
LncRNA MALAT1/Calpain-1 Axis in ATO Induced hERG Channel Deficiency
Yan, C., Li, Y., Li, X., Li, Y., Zhang, Y., Sun, J., Ding, Q., Zhao, X. Y., & Li, B. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s502776 · Cited by 4
Tricyclic Antidepressant Drug Interactions
Walterscheid, J. P., & Danielson, T. J. (2011) · Humana Press eBooks · doi:10.1007/978-1-61779-222-9_5 · Cited by 3
Arsenic‐Induced Cardiovascular Disease
Barchowsky, A., & States, J. C. (2015) · Wiley eBooks · doi:10.1002/9781118876992.ch20 · Cited by 3
Ihsan, M. F., Kawashima, D., Li, S., Ogasawara, S., Murata, T., & Takei, M. (2024) · Lab on a Chip · doi:10.1039/d4lc00230j · Cited by 3
Metadata
- Authors
- Dennis, A., Wang, L., Wan, X., & Ficker, E.
- Affiliations
- MetroHealth (US)
- Venue
- Biochemical Society Transactions
- Publisher
- Portland Press Ltd.
- Published
- 2007-10-25
- Volume
- 35
- Issue
- 5
- Pages
- 1060-1063
- ISSN
- 0300-5127 (ISSN-L)
- 1470-8752
- OpenAlex
- W2063315937
- Cited by
- 134
- References
- 28
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 7 · 2022: 2 · 2021: 4 · 2020: 5 · 2019: 4 · 2018: 5 · 2017: 8 · 2016: 7 · 2015: 4 · 2014: 14 · 2013: 14 · 2012: 8
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemical Society Transactions (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Keywords
- hERG, drug-induced long QT syndrome, acquired long QT syndrome, channel trafficking, cardiac potassium channels, IKr current, torsades de pointes, drug-induced cardiotoxicity, Hsp90 inhibitors, geldanamycin, arsenic trioxide, pentamidine, probucol, fluoxetine, drug safety testing
- MeSH terms
- ERG1 Potassium Channel, Humans, Long QT Syndrome, HSP90 Heat-Shock Proteins, Protein Transport, Ether-A-Go-Go Potassium Channels
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.